Hämostaseologie, Inhaltsverzeichnis Hamostaseologie 1998; 18(S 04): S27-S32DOI: 10.1055/s-0038-1655358 Übersichtsarbeiten/Review Article Schattauer GmbH Anticoagulation: The Old and the New M.M. Samama 1 Service d’Hématologie Biologique, Hôtel-Dieu University Hospital, Paris, France , A. Kher 1 Service d’Hématologie Biologique, Hôtel-Dieu University Hospital, Paris, France› InstitutsangabenArtikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen REFERENCES 1 Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161-2. 2 Wessler S, Gitel N. Pharmacology of heparin and warfarin. J Am Coll Cardiol 1986; 08: 10B-20B. 3 Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337: 688-98. 4 Weitz JI, Hirsh J. New anticoagulant strategies. J Lab Clin Med 1993; 122: 364-73. 5 Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/haemorrhag- ic balance. Thromb Haemost 1997; 78: 357-63. 6 Eriksson BI, Wille-Jørgensen P, Kälebo P. et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-35. 7 The global use of strategies to open occluded coronary arteries (GUSTO) lib Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82. 8 Antman EM for the TIMI 9B investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21. 9 White HD. Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. Thromb Haemost 1997; 78: 364-6. 10 Greinacher A, Völpel H, Pötzsch B. et al. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT). Blood 1996; 88: 281-1. 11 Lewis BE, Grassman E, Wrona L. et al. Successful use of argatroban in coronary angioplasty in patients with heparin induced thrombocytopenia syndrome. Thromb Haemost 1997; Suppl: 494. 12 Thrombin inhibition in myocardial ischae- mia (TRIM) study group. A low molecular weight, selective thrombin inhibitor, inoga- tran, vs heparin, in unstable coronary artery disease in 1209 patients. Europ Heart J 1997; 18: 1416-25. 13 Weaver W, Fung A, Lorch G. et al. Efegatran and streptokinase vs TPA for treatment of acute MI. Circulation 1996; 94: 430. 14 Bounameaux H, Ehringer H, Hulfing J. et al. A trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, RO 466240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis. The Advent trial. Thromb Haemost 1997; 78: 997-1002. 15 Bode C, Kohler B, Steg G. et al. The ecarin clotting time but not the aPTT reliable indicator for PEG-hirudin blood patients with unstable angina pectoris. J Am Coll Cardiol. 1997 29. 411A. 16 Hemker HC, Wielders S, Béguin S. The thrombin potential. A parameter to assess the effect of antithrombotic drugs on thrombin generation. In: Fraxiparine. Second International Symposium. Recent pharmacological and clinical data. HBounameaux M, Samama JW ten Cate. (eds) Schat- tauer; Stuttgart-New-York: 1990; 89-101 17 Kimball SD. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagul Fibrinolysis 1995; 06: 511-9. 18 Harker LA, Hanson SR, Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997; 78: 736-41. 19 Samama MM, Walenga JM, Kaiser B, Fareed J. Specific Factor Xa Inhibitors. Cardiovascular Thrombosis: Thrombocardiolo- gy and Thromboneurology. Second Edition: Verstraete M, Fuster V, Topol EJ. (eds) Philadelphia: Lippincott-Raven Publishers; 1998 20 Herbert JM, Petitou M, Lormeau JC. et al. SR 90107 A/ORG 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15: 1-26. 21 Kunitada S, Nagahara T. Factor Xa Inhibitors. Current Pharmaceutical Design 1996; 02: 531-42. 22 Rebello SS, Lucchesi Br. Recombinant nematode anticoagulant peptide (rNAP5), a selective factor Xa inhibitor, prevents canine coronary artery thrombosis. Circulation 1996; 94: 1-267. 23 Hara T, Yokohama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 1995; 80: 99-104. 24 Taniuchi Y, Sakai Y, Kawasaki T. et al. Anticoagulant and pharmacokinetic profiles of YM-60828, an orally active and potent synthetic inhibitor of factor Xa. Thromb Haemost 1997; 78: 294. 25 Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-7. 26 Weitz JI, Hirsh J. Review of new developments in heparins, thrombin inhibitors and other new and novel agents. In: New therapeutic agents in thrombosis and thrombolysis. Sasahara AA, Loscalzo J 1997; 77: 86. 27 Vlasuk GP, Bergum PW, Rote WE. Mechanistic and pharmacological evaluation of NAPc2, a novel small protein inhibitor of the factor Vila/tissue factor complex. Thromb Haemost 1997; 78: 688. 28 Cooks JJ, Sitko GR, Bednar B, Condra C, Mellott MJ, Feng DM, Nutt RF, Sahfer JA, Gould RJ, Connolly TM. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 1995; 91: 2961-71. 29 Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-36.
